Vol. 6 No. 2 (2026)
Reimbursement Reviews

Odevixibat (Bylvay)

decorative image of the issue cover

Published February 17, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Odevixibat (Bylvay), 200 mcg, 400 mcg, 600 mcg, and 1,200 mcg oral capsules.
  • Indication: For the treatment of cholestatic pruritus in patients aged 12 months or older with ALGS.